Exact Sciences for transplant patient monitoring.

Epic Systems for transplant centers, combined with crucial diagnostic tests.

CareDx (CDNA) offers the following major products and services:

• AlloSure Kidney: A donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients.
• AlloMap Heart: A gene expression solution for heart transplant patients.
• AlloSure Heart: A donor-derived cell-free DNA (dd-cfDNA) solution for heart transplant patients.
• AlloSure Lung: A donor-derived cell-free DNA (dd-cfDNA) solution for lung transplant patients.
• TruSight HLA: A next-generation sequencing (NGS) based high-resolution human leukocyte antigen (HLA) typing solution.
• Olerup SSP: A solution used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology.
• QTYPE: A technology that enables precision in human leukocyte antigen (HLA) typing.
• Ottr: A transplant patient management software.
• AlloSeq Tx: A high-resolution human leukocyte antigen (HLA) typing solution.
• AlloSeq cfDNA: A surveillance solution to measure donor-derived cell-free DNA in blood.
• AlloSeq HCT: A solution for chimerism testing for stem cell transplant recipients.
• XynQAPI: Transplant quality tracking and waitlist management solutions.
• AlloCare: A mobile application that offers a patient-centric resource for transplant recipients.
• iBox: Software for the predictive analysis of post-transplantation kidney allograft loss, commercialized via a license agreement.

• Transplant Centers and Hospitals: These institutions are the primary users of CareDx's diagnostic solutions for transplant patients (such as AlloSure, AlloMap, and HLA typing products) and its transplant patient management software (like Ottr and XynQAPI).
• Clinical Laboratories: Specialized clinical laboratories utilize CareDx's high-resolution HLA typing, chimerism testing, and surveillance solutions (e.g., TruSight HLA, AlloSeq cfDNA, AlloSeq HCT) to perform diagnostic tests.
• Third-Party Distributors and Sub-Distributors: CareDx uses a network of distributors to reach its end customers (hospitals, transplant centers, and labs) globally. These distributors are direct customers of CareDx.

• Illumina, Inc. (Symbol: ILMN)
• Cibiltech SAS

John W. Hanna, President and Chief Executive Officer

John W. Hanna assumed the role of President and Chief Executive Officer and became a member of the board of directors on April 15, 2024. He brings over two decades of executive leadership experience at the intersection of new technology development and revenue growth within the molecular diagnostics and life sciences tools industries. Prior to joining CareDx, Mr. Hanna served as Chief Executive Officer of Apton Biosystems, Inc., where he spearheaded the development of a high-throughput next-generation sequencing (NGS) platform. Apton Biosystems, Inc. was subsequently acquired by Pacific Biosciences of California, Inc. His previous experience also includes leadership roles at Veracyte, Inc., Humana, and IBM.

Keith Kennedy, Chief Operating Officer and Chief Financial Officer

Keith Kennedy was appointed Chief Operating Officer and Chief Financial Officer, effective February 26, 2026. He has served as CareDx's Chief Operating Officer since September 2024. Mr. Kennedy brings over 20 years of experience and executive leadership in healthcare, including global diagnostics and biopharma services. Before joining CareDx, he served as CFO at PharmaLogic Holdings Corp from April 2022 to September 2024. At Veracyte, he held various roles from December 2016 to May 2021, including Chief Operating Officer, Chief Financial Officer, and Secretary. He also held key executive positions at MCG Capital Corporation and GE Capital and served as an Officer in the U.S. Air Force. Mr. Kennedy is a Chartered Financial Analyst and Certified Public Accountant.

Marica Grskovic, Ph.D., Chief Strategy Officer

Marica Grskovic, Ph.D., was appointed Chief Strategy Officer in December 2024. Dr. Grskovic has been with CareDx since 2012 and has played a key role in leading the development of the AlloSure® product. Her background includes strong experience in operations, research and development, and pharmaceutical partnering, and she holds a Doctorate in Molecular Biology and Biochemistry.

Jessica Meng, Chief Commercial Officer

Jessica Meng was appointed Chief Commercial Officer in December 2024. She brings commercial strategy experience from her previous roles at DELFI Diagnostics and Myovant Sciences, as well as leadership positions at Veracyte and Genentech. Ms. Meng holds a dual Bachelor of Science in Finance and a Bachelor of Arts in International Relations from the University of Pennsylvania, along with an MBA from The Wharton School.

The key risks to CareDx (CDNA) largely stem from regulatory scrutiny, evolving reimbursement policies, and challenges in achieving consistent profitability amidst a competitive landscape.

1. Regulatory Investigations and Litigation: CareDx faces ongoing federal investigations by the Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) into its business practices, particularly concerning kidney testing and phlebotomy services. These investigations also include allegations of improper and illegal schemes to inflate revenue. The company has also been subject to securities class action lawsuits alleging failure to disclose material information. Such legal and regulatory challenges can lead to significant financial liabilities, reputational damage, and impact the company's market position.
2. Regulatory Risks and Reimbursement Changes: A significant risk for CareDx involves changes in Medicare and other insurance coverage and reimbursement policies for its diagnostic products and services. Specifically, a draft local coverage determination (LCD) policy for molecular allograft testing could materially impact the company's annual revenue. Shifts in reimbursement policies present continuous risks around future revenue streams and profitability.
3. Lack of Consistent Profitability and Intensifying Competition: Despite its specialized product portfolio and revenue growth, CareDx has historically struggled to achieve consistent operating profitability. The company operates in a fragmented and increasingly competitive market, with new diagnostic tests and AI-driven solutions emerging. This intensifying competition, coupled with the need for continuous innovation, poses a risk to market share, pricing power, and long-term earnings momentum.

Natera, Inc. (NTRA) poses a clear emerging threat through its Prospera donor-derived cell-free DNA (dd-cfDNA) test. Prospera directly competes with CareDx's AlloSure suite of products (AlloSure Kidney, AlloSure Heart, AlloSure Lung), which are central to CareDx's business in post-transplant surveillance. Natera is a well-capitalized and established diagnostics company actively expanding its market share in the transplant diagnostics space, directly challenging CareDx's leadership in this critical segment.

CareDx, Inc. (CDNA) operates in several key areas within the transplant diagnostics and patient management markets. The addressable markets for its main products and services include:

Transplant Diagnostics (Overall Market)

The global transplant diagnostics market was valued at approximately USD 6.39 billion in 2024 and is projected to reach USD 12.15 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 7.45% from 2025 to 2033. North America held the largest global revenue share, accounting for 32.52% of the market in 2024. Within North America, the U.S. transplant diagnostics market was valued at USD 1.41 billion in 2023 and is expected to reach USD 2.28 billion by 2032, growing at a CAGR of 5.46% over the forecast period 2024-2032.

The post-transplantation monitoring segment of the global transplant diagnostics market, which is highly relevant for CareDx's AlloSure and AlloMap products, held a substantial market share in 2022, valued at around USD 2.1 billion.

Donor-Derived Cell-Free DNA (dd-cfDNA) Testing (AlloSure Kidney, AlloSure Heart, AlloSure Lung, AlloSeq cfDNA)

The global donor-derived cell-free DNA (dd-cfDNA) testing market was valued at USD 605 million in 2024 and is projected to expand to USD 2,120 million by 2033, demonstrating a robust CAGR of 15.2% from 2025 to 2033. North America currently dominates this market. For kidney transplant dd-cfDNA testing, the addressable market for regulated transplant rejection testing is estimated at roughly $2 billion-plus (global).

Specifically for CareDx's products in the U.S.:

• The total annual market for AlloSure Kidney is estimated at approximately $437.5 million.
• Post-heart transplant testing, which includes AlloMap Heart and AlloSure Heart, could be worth up to $252 million annually.

CareDx's tests for kidney, heart, and lung operate within a broader total addressable market for organ transplants in the United States, which is estimated at $20 billion.

HLA Typing (TruSight HLA, Olerup SSP, QTYPE, AlloSeq Tx)

The global HLA typing market size was estimated at USD 1.62 billion in 2024 and is expected to reach USD 2.69 billion by 2032, growing at a CAGR of 6.58% during the forecast period of 2025-2032. North America accounted for the largest share of the HLA typing market in 2024. The U.S. HLA typing market size was valued at USD 0.64 billion in 2024 and is expected to reach USD 0.98 billion by 2032.

Transplant Patient Management Software (Ottr, XynQAPI, AlloCare)

The U.S. organ donation and transplant software market was estimated at USD 57.16 million in 2025 and is projected to reach USD 90.04 million by 2033, growing at a CAGR of 5.9% from 2026 to 2033. This market growth is driven by increasing organ transplant volumes, the prevalence of end-stage organ diseases, and regulatory requirements for standardized data reporting.

CareDx, Inc. (CDNA) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

1. Increased Testing Services Volume: CareDx anticipates continued growth in the volume of its core testing services, including AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. This growth is expected to be fueled by increased adoption of surveillance protocols and expanded "for-cause" utilization of these tests at transplant centers. For example, kidney testing has shown strong growth, supported by both increased surveillance protocol adoption and expanded for-cause use of AlloSure Kidney at transplant centers. The company reported approximately 53,000 tests in Q4 2025, up 17% year-over-year. Management expects testing services volume to grow in the mid-teens year-over-year in 2025.
2. Expansion of Payer Coverage and Average Selling Price (ASP) Improvement: CareDx is focused on expanding insurance coverage for its diagnostic solutions, which directly contributes to increased revenue per test (ASP). In 2024, the company added or expanded coverage for 28 million lives for AlloMap Heart and 36 million new commercial covered lives for AlloSure, with continued efforts to drive ASP in future quarters through improved coverage and disciplined revenue cycle management. Increased average revenue-per-test was a factor in the improved non-GAAP gross margin in Q3 2025.
3. Growth in Patient and Digital Solutions: The Patient and Digital Solutions segment, which includes transplant patient management software (Ottr, XynQAPI), transplant pharmacy services, and remote patient monitoring, is a significant growth driver. This segment has consistently shown strong year-over-year growth, with a 47% increase in Q4 2025 compared to the previous year and a 31% increase for the full year 2025.
4. Introduction of New Products and Pipeline Advancement: CareDx's pipeline advancements and the potential launch of new diagnostic solutions are expected to drive future revenue. A notable example is AlloHeme, for which ACROBAT data demonstrated earlier detection of relapse, with plans for CLIA readiness in 2026 and a commercial launch in early 2027. The company emphasizes pipeline advancement as a key growth driver to sustain product innovation.
5. Enhanced Go-to-Market Strategy and Sales Force Expansion: The company is leveraging its go-to-market strategy to provide comprehensive solutions to transplant centers across the care continuum. CareDx has notably expanded its sales force by approximately 50%, which is anticipated to further enhance volume growth and strengthen its competitive position.

Share Repurchases

• CareDx authorized a common stock repurchase program of up to $50 million in December 2022, spanning a period of up to 24 months.
• By June 2025, the company completed a $50 million repurchase of its common stock, representing approximately 5% of outstanding shares.
• For the full year 2025, CareDx repurchased $88 million of stock. Following the completion of this program, a new share repurchase program of up to $50 million was authorized in June 2025 for the subsequent 24 months.

Outbound Investments

• CareDx has made a total of 8 acquisitions, with the most active period being 2021, when four acquisitions were completed.
• The most recent acquisition was MediGO in July 2023, a software provider specializing in organ transplantation management.
• The company's strategy includes continued investment in strategic acquisitions to advance its goals and deliver long-term shareholder value.

Capital Expenditures

• CareDx invested $3.6 million in capital expenditures during Q3 2021, primarily directed towards funding long-term assets and infrastructure.
• For 2026, the company plans strategic investments of approximately $10 million in enterprise systems, including Epic Enterprise LIMS, which are expected to contribute significantly to future growth.